High
2.500
Open
2.450
VWAP
--
Vol
156.60K
Mkt Cap
237.97M
Low
2.350
Amount
--
EV/EBITDA(TTM)
--
Total Shares
98.90M
EV
85.15M
EV/OCF(TTM)
1.69
P/S(TTM)
7.61
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2024Q4
1.98M
+188.57%
--
--
742.32K
-94.98%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for AC Immune SA (ACIU) for FY2025, with the revenue forecasts being adjusted by -85.57% over the past three months. During the same period, the stock price has changed by 39.41%.
Revenue Estimates for FY2025
Revise Downward

-85.57%
In Past 3 Month
Stock Price
Go Up

+39.41%
In Past 3 Month
3 Analyst Rating

308.02% Upside
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 9.67 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

308.02% Upside
Current: 2.370

Low
8.00
Averages
9.67
High
12.00

308.02% Upside
Current: 2.370

Low
8.00
Averages
9.67
High
12.00
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-04-03
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-04-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2025-03-14
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2025-03-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2024-11-15
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2024-11-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2024-11-06
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2024-11-06
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$16
2024-09-18
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$16
2024-09-18
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for AC Immune SA (ACIU.O) is -2.57, compared to its 5-year average forward P/E of -6.80. For a more detailed relative valuation and DCF analysis to assess AC Immune SA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-6.80
Current PE
-2.57
Overvalued PE
3.28
Undervalued PE
-16.88
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-11.73
Current EV/EBITDA
-8.45
Overvalued EV/EBITDA
20.05
Undervalued EV/EBITDA
-43.52
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
43.65
Current PS
29.51
Overvalued PS
144.50
Undervalued PS
-57.19
Financials
Annual
Quarterly
FY2025Q1
990.00K
Total Revenue
FY2025Q1
YoY :
-3.48%
-19.37M
Operating Profit
FY2025Q1
YoY :
+6.53%
-19.03M
Net Income after Tax
FY2025Q1
YoY :
+5.56%
-0.19
EPS - Diluted
FY2025Q1
YoY :
-2574.58%
-19.18M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-154.56%
160.12
FCF Margin - %
FY2025Q1
-1.92K
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
659.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
300.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ACIU News & Events
Events Timeline
2025-04-30 (ET)
2025-04-30
07:02:51
AC Immune reports Q1 EPS (19c) vs (18c) last year

2025-04-02 (ET)
2025-04-02
06:02:19
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial

2025-03-13 (ET)
2025-03-13
07:11:38
AC Immune reports FY24 EPS (51c), consensus (54c)

Sign Up For More Events
Sign Up For More Events
News
4.0
05-01BenzingaHC Wainwright & Co. Maintains Buy on AC Immune, Lowers Price Target to $12
4.0
04-03BenzingaHC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
9.0
04-02NewsfilterAC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
Sign Up For More News
People Also Watch

NATR
Nature's Sunshine Products Inc
14.730
USD
+0.14%

FLXS
Flexsteel Industries Inc
36.700
USD
-0.35%

SKIL
Skillsoft Corp
14.950
USD
+1.77%

ICG
Intchains Group Ltd
2.824
USD
-0.56%

PERF
Perfect Corp
2.450
USD
-2.78%

GMGI
Golden Matrix Group Inc
1.610
USD
-1.83%

THRD
Third Harmonic Bio Inc
5.380
USD
-0.55%

FTK
Flotek Industries Inc
12.130
USD
-1.78%
FAQ

What is AC Immune SA (ACIU) stock price today?
The current price of ACIU is 2.37 USD — it has decreased -2.47 % in the last trading day.

What is AC Immune SA (ACIU)'s business?

What is the price predicton of ACIU Stock?

What is AC Immune SA (ACIU)'s revenue for the last quarter?

What is AC Immune SA (ACIU)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for AC Immune SA (ACIU)'s fundamentals?

How many employees does AC Immune SA (ACIU). have?
